Overview

This trial is active, not recruiting.

Condition non-squamous non-small cell lung cancer
Target VEGF
Sponsor Hoffmann-La Roche
Start date March 2013
End date June 2017
Trial size 1107 participants
Trial identifier NCT01827852, ML28306

Summary

This prospective observational study will evaluate the efficacy and safety of first-line Avastin (bevacizumab) in combination with platinum-based chemotherapy in different age groups (<60, 60-69, 70-79, >80 years) in patients with inoperable advanced, metastatic or recurrent adenocarcinoma non-small cell lung cancer. Patients will be followed for 18 months from the start of first-line therapy.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm

Primary Outcomes

Measure
Progression-free survival in 4 different age groups (<60, 60-69, 70-79, >/=80 years)
time frame: approximately 4.5 years

Secondary Outcomes

Measure
Overall survival in 4 different age groups (<60, 60-69, 70-79, >/=80 years)
time frame: approximately 4.5 years
Clinical/demographic patient characteristics at initiation of treatment
time frame: approximately 4.5 years
Avastin treatment schedule in routine clinical practice (dosage/duration)
time frame: approximately 4 years
Concomitant anti-neoplastic therapy (dosage/duration)
time frame: approximately 4.5 years
Safety: Incidence of adverse events in 4 different age groups (<60, 60-69, 70-79, >/=80 years)
time frame: approximately 4.5 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Adult patients, >/= 18 years of age - Histologically confirmed inoperable advanced, metastatic or recurrent pre-dominantly non-squamous adenocarcinoma non-small cell lung cancer Exclusion Criteria: - Contraindications to Avastin treatment according to the Summary of Product Characteristics

Additional Information

Official title AVAdeno: Non-interventional Study of Avastin 1st Line Therapy in Adenocarcinoma Patients of the Lung
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by Hoffmann-La Roche.